Keyphrases
Rheumatoid Arthritis
100%
Treatment Group
100%
Drug Treatment
100%
Lymphoma
100%
Collaborative Projects
100%
European Registries
100%
Biologic Disease-modifying Antirheumatic Drugs
83%
Lymphoma Subtype
50%
Hodgkin Lymphoma
33%
Tumour Necrosis Factor Inhibitor (TNFi)
33%
Diffuse Large B-cell Lymphoma (DLBCL)
33%
Type Distribution
33%
B-cell non-Hodgkin Lymphoma (B-NHL)
33%
First-ever
16%
Malignant Disease
16%
Collaborative Analysis
16%
First Dose
16%
Non-Hodgkin Lymphoma
16%
Chronic Lymphocytic Leukemia
16%
Biologics Register
16%
Heterogeneous Groups
16%
T-cell non-Hodgkin Lymphoma
16%
Hepatosplenic T-cell Lymphoma
16%
B-cell NHL
16%
Medicine and Dentistry
Drug Therapy
100%
Rheumatoid Arthritis
100%
Biological Product
100%
Disease Modifying Antirheumatic Drug
100%
Non-Hodgkin Lymphoma
80%
B Cell
60%
Population
40%
Hodgkin's Lymphoma
40%
TNF Inhibitor
40%
Diffuse Large B-Cell Lymphoma
40%
Disease
20%
T Cell
20%
B-Cell Chronic Lymphocytic Leukemia
20%
Hepatosplenic T-Cell Lymphoma
20%
Pharmacology, Toxicology and Pharmaceutical Science
Pharmacotherapy
100%
Rheumatoid Arthritis
100%
Biological Product
100%
Disease Modifying Antirheumatic Drug
100%
Nonhodgkin Lymphoma
80%
Tumor Necrosis Factor Inhibitor
40%
Diffuse Large B Cell Lymphoma
40%
Hodgkin Disease
40%
Disease
20%
Chronic Lymphatic Leukemia
20%
T Cell Lymphoma
20%
Immunology and Microbiology
Inflammatory Arthritis
100%
Biological Product
100%
Disease-Modifying Antirheumatic Drug
100%
B Cell
80%
Population
40%
T Cell
40%
TNF Inhibitor
40%